An Open-label, Multicenter Study Assessing Efficacy and Safety of Secukinumab up to One Year in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed informed consent must be obtained before any assessment is performed.
• Chinese male and female participants ≥ 18 years of age.
• Confirmed/documented diagnosis of HS ≥ 6 months prior to baseline.
• Participants with moderate to severe HS at baseline defined as:
‣ A total of at least 5 inflammatory lesions, i.e., abscesses and/or inflammatory nodules AND
⁃ Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae)
Locations
Other Locations
China
Novartis Investigative Site
RECRUITING
Beijing
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+1-888-669-6682
Backup
Novartis Pharmaceuticals
+41613241111
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2029-11-05
Participants
Target number of participants: 36
Treatments
Experimental: Secukinumab Q2W
Participants receive secukinumab administered every two weeks (Q2W) at the specified dose
Experimental: Secukinumab Q4W
Participants receive secukinumab administered every four weeks (Q4W) at the specified dose
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals